Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q2 2020 · 10-Q
Revenue$0.00$0.00— vs Q2 2019 Net Income-$314.89K-$314.89KN/M vs Q2 2019 EPS Diluted$0.00$0.00— vs Q2 2019 Operating Income-$315,044N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
derived
ended Jun 30, 2020 · filed Aug 12, 2020 · 43 d after period end